Jump to content

Moderna's new Omicron-targeted booster shot shows promise


Recommended Posts

Posted

Screenshot_2.jpg.542527f4f0ebe769bcafbd09970666fc.jpg

 

Company says they hope the new vaccine can provide six to nine months of protection

 

Moderna’s MRNA experimental next-generation COVID-19 vaccine provides more protection against omicron than the original shot, and the company is aiming to make it available to Americans this summer.

 

What’s different about this shot — called a “bivalent” vaccine — than the currently available boosters is that one half of the formation targets omicron, whose subvariants like BA.2 and BA.2.12.1 are currently the most dominant strains of the virus circulating in the U.S. 

 

The other half is still based on the ancestral strain of SARS-CoV-2, which was first detected in China in 2019. All approved and authorized COVID-19 vaccines are based are on this strain.

 

“We’re pretty confident that this vaccine is going to provide a benefit even against the family of omicron variants and subvariants,” Moderna President Stephen Hoge said during a call with investors on Wednesday.

 

(more)

 

https://www.marketwatch.com/story/modernas-next-generation-covid-19-shot-provides-superior-protection-against-omicron-11654703308?mod=investing

 

MarketWatch.jpg.77ba3a18202261c6a41a2f436f469ef6.jpg

 

 

Also:

Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

 

CAMBRIDGE, MA / ACCESSWIRE / June 8, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern. A 50 µg booster dose of mRNA-1273.214 met all pre-specified endpoints including superior neutralizing antibody response (geometric mean ratio) against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine. The booster dose of mRNA-1273.214 was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 µg dose level.

 

"We are thrilled to share the preliminary data analysis on mRNA-1273.214, which is the second demonstration of superiority of our bivalent booster platform against variants of concern and represents an innovation in the fight against COVID," said Stéphane Bancel, Chief Executive Officer of Moderna.

 

(more)

 

https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx

 

 

 

  • Like 1

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.



×
×
  • Create New...